In patients with multivessel coronary artery disease, PCI using everolimus-eluting stents led to a higher rate of major adverse cardiovascular events compared to CABG.
Does PCI with everolimus-eluting stents improve major adverse cardiovascular events in patients with multivessel coronary artery disease compared to CABG?
In patients with multivessel coronary artery disease, CABG is associated with a lower rate of major adverse cardiovascular events compared to PCI with everolimus-eluting stents.
Among patients with multivessel coronary artery disease, the rate of major adverse cardiovascular events was higher among those who had undergone PCI with the use of everolimus-eluting stents than among those who had undergone CABG. (Funded by CardioVascular Research Foundation and others; BEST ClinicalTrials.gov number, NCT00997828.).
Park et al. (2015) studied this question. In patients with multivessel coronary artery disease, PCI using everolimus-eluting stents led to a higher rate of major adverse cardiovascular events compared to CABG.